Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Lamisil AT 1% Gel

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Terbinafine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Terbinafine
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

FOR Lamisil AT 1% Gel contains the active ingredient terbinafine which is an antifungal used to treat skin problems caused by fungi in:

  • Athlete's foot (tinea pedis) – athlete's foot appears only on the feet (usually both, but not always), where it often appears in-between the toes. It can also appear on the instep, soles, or other areas of the feet. The most common type of athlete's foot causes cracking or scaling of the skin, but you may also have mild swelling, blisters, or weeping ulcers. Lamisil AT 1% Gel is recommended for athlete's foot when it occurs between the toes. If you have a fungal nail infection (fungus inside and under the nail) with discolouration of the nails and changes in nail texture (thick or flaky), you should consult your doctor because Lamisil AT 1% Gel is not appropriate for this type of infection.
  • Dhobie itch/jock itch (tinea cruris) – dhobie itch appears in the groin and inner thigh area, usually on both sides but often with one side more than the other, where it can spread further between the legs to the buttocks, or up towards the stomach. Dhobie itch looks like a clearly bordered rash, which may have blisters.
  • Ringworm (tinea corporis) – ringworm usually appears as circular, sharp-edged areas of red rash, with dry, scaly or

2. BEFORE YOU USE LAMISIL AT 1% GEL DO NOT use Lamisil AT 1% Gel if you have:

  • an allergy (hypersensitivity) to any of the ingredients in the product (see Section 6 and end of Section 2). The gel is NOT recommended for children under 16 years of age. Take special care with Lamisil AT 1% Gel The gel is for application on the skin only.
  • Avoid inhaling the product.
  • Eyes, mouth or face – avoid contact of the gel. In case of accidental contact with eyes, rinse thoroughly with running water. Taking other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including those obtained without a prescription. Do not apply other medicines on the areas you are treating with Lamisil AT 1% Gel. Pregnancy and breast-feeding If you are pregnant ask your doctor before using this medicine. Do not use the gel if you are breast-feeding. Driving and using machines Lamisil AT 1% Gel is not expected to affect your ability to drive or operate machinery. Important information about some of the ingredients of Lamisil AT 1% Gel Butylated hydroxytoluene (E321) – may cause local skin reactions (e.g. contact dermatitis), or irritation to the eyes and membrane linings. Benzyl alcohol – contains 10.8 mg benzyl alcohol in each daily dosage which is equivalent to 5 mg/g. Benzyl alcohol may cause allergic reactions. Ethanol – contains 207.36 mg alcohol (ethanol) in each daily dose which is equivalent to 100 mg/g of 96% ethanol. It may cause burning sensation on damaged skin.

How to take it

LAMISIL AT 1% GEL Always use this medicine exactly as described in this leaflet or as advised by your doctor or pharmacist. Adults Lamisil AT 1% Gel is applied once a day, for one week only, for all fungal infections.

  • Cleanse and dry the affected areas thoroughly and wash your hands. Treatment can be helped by keeping the affected areas clean by regular washing and careful drying with your own clean towels and clothes, and not rubbing or scratching the skin.
  • Unscrew the cap – if using the medicine for the first time, use the point in the cap to pierce the top of the tube then gently squeeze out the gel. 5054793 GB / 2003443_1

25

1% GEL

4. POSSIBLE SIDE EFFECTS Like all medicines, Lamisil AT 1% Gel can cause side effects, although not everybody gets them. STOP using the gel and seek medical help immediately if you have any of the following very rare allergic reactions:

  • Difficulty breathing or swallowing, swelling of the mouth, face, lips, tongue or throat (severe allergic reaction).
  • Severe itching of the skin, with red rash or raised lumps, hives or blisters. Common (may affect up to 1 in 10 people): skin peeling, itching. Uncommon (may affect up to 1 in 100 people): skin lesions, scab, skin colour changes, redness, burning, pain and irritation at the site of application. These common and uncommon side effects are usually harmless and you can carry on using the gel. Rare (may affect up to 1 in 1000 people): eye irritation, dry skin, contact dermatitis, eczema, worsening of symptoms. If any of these side effects get serious, or if you notice any

Possible side effects

not listed in this leaflet, please tell your doctor. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow

Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

How to store it

LAMISIL AT 1% GEL Keep out of the sight and reach of children. Do not store above 30°C. Use this medicine within 1 month of opening. Do not use or keep this medicine after the expiry (EXP) date shown on the box and tube. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

6. FURTHER INFORMATION What Lamisil AT 1% Gel contains The active ingredient is terbinafine, 1% w/w. The other ingredients are purified water, ethanol, isopropyl myristate, polysorbate 20, carbomer 974P, sorbitan laurate, benzyl alcohol, sodium hydroxide and butylated hydroxytoluene (see also Section 2 'Important information about some of the ingredients of Lamisil AT 1% Gel'). What Lamisil AT 1% Gel looks like and contents of the pack The gel is available in a 15g aluminium or laminated screw cap tube. Marketing Authorisation Holder Karo Healthcare AB, Box 16184, 103 24 Stockholm, Sweden. Manufacturer Karo Healthcare AB, Klara Norra Kyrkogata 33, 111 22 Stockholm, Sweden. This leaflet was last revised in December 2023.

25

25

  • Rub the gel in lightly to the affected skin and surrounding areas (avoid application to where alcohol could cause stinging or irritation). When used between the toes, buttocks or on the groin, the treated area may be covered with a light, fresh gauze strip, especially at night.
  • Replace the cap on the tube and wash your hands. Even though you will not be using Lamisil AT 1% Gel during the second week, full skin healing after the infection has cleared will continue for up to 4 weeks. If you have not noticed any signs of improvement within 2 weeks of first starting treatment, please seek advice from your doctor or pharmacist. Children under 16 years NOT recommended. If you accidently swallow Lamisil AT 1% Gel Contact your doctor or nearest hospital emergency department if you, or someone else, has swallowed some gel. Take any remaining medicine and this leaflet with you if possible. Symptoms of accidental ingestion include headache, nausea (feeling sick), dizziness and stomach pain. If you forget to use Lamisil AT 1% Gel If you miss an application, apply the gel as soon as possible then carry on as before. If you only remember at the time of your next application, just apply the gel and carry on as normal. It is important to try to use the gel at the correct times as forgotten applications could risk the infection returning. If you stop using Lamisil AT 1% Gel You should not stop using the gel before the recommended time as this may reduce the effectiveness of treatment or the infection may return. If you have any further questions on the use of this product, ask your doctor or pharmacist.

5054793 GB / 2003443_1

Frequently asked questions about Lamisil AT 1% Gel

How do I take Lamisil AT 1% Gel?

Lamisil AT 1% Gel comes as gel. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Lamisil AT 1% Gel?

The active substance in Lamisil AT 1% Gel is terbinafine.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Lamisil AT 1% Gel, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Lamisil AT 1% Gel without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Terbinafine (1 medicine)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

The treatment of tinea pedis (athlete's foot), tinea cruris (dhobie (jock) itch) and tinea corporis (ringworm) caused by Trichophyton (e.g. T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum) and Epidermophyton floccosum.

4.2. Posology and method of administration

Adults

Lamisil AT 1% Gel is applied once daily for all indications.

Duration and frequency of treatment

Tinea corporis, tinea cruris

Tinea pedis (interdigital type)

1 week once a day

1 week once a day

Relief of clinical symptoms usually occurs within a few days. Irregular use or premature discontinuation of treatment carries the risk of recurrence. If there are no signs of improvement after two weeks, the diagnosis should be verified by a physician.

Dosing in special populations

Paediatric populations

Not to be used in children under 16 years of age. Experience with Lamisil AT 1% Gel in children is limited and its use cannot therefore be recommended.

Elderly patients

There is no evidence to suggest that elderly patients require different dosages or experience side effects different from those in younger patients.

Method of Administration

For cutaneous use.

Cleanse and dry the affected areas thoroughly before applying Lamisil AT 1% Gel. The gel should be rubbed in lightly to the affected skin and surrounding area. In the case of intertriginous infection (submammary, interdigital, intergluteal, inguinal) the application may be covered with a light gauze, especially at night.

4.3. Contraindications

Known hypersensitivity to terbinafine or any of the excipients contained in the gel (see section 6.1 List of Excipients).

4.4. Special warnings and precautions for use

Lamisil AT 1% Gel contains 207.36 mg alcohol (ethanol) in each daily dose which is equivalent to 100 mg/ g of 96% ethanol. Lamisil AT 1% Gel should be used with caution in patients with lesions where alcohol could be irritating, such as lesions which are markedly inflamed or on sensitive areas of the body such as the face.

Lamisil AT 1% Gel is for external use only. It may be irritating to the eyes. In case of accidental contact with the eyes, rinse eyes thoroughly with running water.

Lamisil AT 1% Gel contains butylhydroxytoluene (E321), which may cause local skin reactions (e.g. contact dermatitis), or irritation to the eyes and mucous membranes.

Lamisil AT 1% Gel contains 10.8 mg benzyl alcohol in each daily dosage which is equivalent to 5 mg/g. Benzyl alcohol may cause mild local irritation.

4.5. Interaction with other medicinal products and other forms of interaction

No drug interactions are known with Lamisil AT 1% Gel, however as a precaution it is recommended that other medicinal products are not applied on the treated areas.

4.6. Fertility, pregnancy and lactation

Pregnancy

Animal studies did not reveal any teratogenic or embryofoetotoxic potential of terbinafine.

No cases of malformation in humans have been reported with terbinafine to date. There is limited clinical experience in pregnant women, Lamisil AT 1% Gel should not be used during pregnancy unless clearly indicated.

Lactation

Terbinafine is excreted in breast milk. Therefore, mothers should not use Lamisil AT 1% Gel whilst breastfeeding. Infants must not be allowed to come into contact with any treated skin, including the breast.

Fertility

No effect of terbinafine on fertility have been seen in animal studies (see section 5.3).

4.7. Effects on ability to drive and use machines

Lamisil AT 1% Gel has no influence on the ability to drive and use machines

4.8. Undesirable effects

Local symptoms such as pruritus, skin exfoliation, application site pain, application site irritation, pigmentation disorder, skin burning sensation, erythema, scab may occur at the site of application.

These minor symptoms must be distinguished from hypersensitivity reactions such as widespread pruritus, rash, bullous eruptions and hives, which are reported in sporadical cases but require discontinuation.

In case of accidental contact with the eyes terbinafine hydrochloride may be irritating to the eyes.

In rare cases the underlying fungal infection may be aggravated.

Immune system disorders

Not known: Hypersensitivity

Eye disorders

Rare: Eye irritation

Skin and subcutaneous tissue disorders

Common: Skin exfoliation, pruritus

Uncommon: Skin lesion, scab, skin disorder, pigmentation disorder, erythema, skin burning sensation

Rare: Dry skin, dermatitis contact, eczema

Not known: Rash

General disorders and administration site conditions

Uncommon: Pain, application site pain, application site irritation

Rare: Condition aggravated

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

4.9. Overdose

The low systemic absorption of topical terbinafine renders overdosage extremely unlikely.

Accidental ingestion of one 30 g tube of Lamisil 1% Gel, which contains 300 mg terbinafine base, is comparable to ingestion of one Lamisil 250 mg tablet (adult oral unit dose).

Should a larger amount of Lamisil AT 1% Gel be inadvertently ingested, adverse effects similar to those observed with an overdosage of Lamisil tablets are to be expected. These include headache, nausea, epigastric pain and dizziness.

In case of accidental oral ingestion, the alcohol content has to be considered:

Lamisil AT 1% Gel contains 9.4% w/w alcohol.

Treatment of overdoseIf accidentally ingested, the recommended treatment of overdosage consists of eliminating the active substance, primarily by the administration of activated charcoal, and giving symptomatic supportive therapy if needed.

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

  • FUNGISIL MK 10 mg/g over the counterTERBINAFINUM · skin / topical
  • LAMISIL 10 mg/g over the counterTERBINAFINUM · skin / topical
  • EXOTERFYN 78,22 mg/ml over the counterTERBINAFINUM · skin / topical
  • TAFICEN 10 mg/g over the counterTERBINAFINUM · skin / topical
  • TERBINAFINA OZONE 10 mg/g over the counterTERBINAFINUM · skin / topical
  • TERBINAFINA SLAVIA 10 mg/g over the counterTERBINAFINUM · skin / topical

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

⚠ Same active substance, but a different pharmaceutical form (for example a gel instead of a tablet). Not interchangeable — ask a pharmacist.

  • LamisilattTerbinafini hydrochloridum
  • LamisilTerbinafini hydrochloridum · taken by mouth
  • TerbidermTerbinafini hydrochloridum
  • MyconafineTerbinafinum · taken by mouth
  • Undofen MaxTerbinafini hydrochloridum
  • ErfinTerbinafinum · taken by mouth

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Lamisil AT 1% Gel. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →